Results 41 to 50 of about 186,761 (273)

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors [PDF]

, 2020
Small molecular PD‐1 inhibitors are lacking in current immuno‐oncology clinic. PD‐1/PD‐L1 antibody inhibitors currently approved for clinical usage block interaction between PD‐L1 and PD‐1 to enhance cytotoxicity of CD8+ cytotoxic T lymphocyte (CTL ...
Chen, Liang, Chen, Zhipeng, Coleman, James, Ding, Ke, Dong, Changjiang, Fan, Zhenzhen, Gao, Song, He, Jingjing, Huang, Junqi, Li, Nan, Liu, Lu, Tian, Yahui, Xu, Chenqi, Zhang, Zhimin, Zhou, Penghui, Zhou, Qian   +15 more
core   +1 more source

Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation

Respiratory Medicine Case Reports, 2019
A 66-year-old Japanese man with recurrent adenocarcinoma of the lung p-stage IIIA (pT2bN2M0; version 8) on pembrolizumab was present with gradually worsening dyspnea.
Ryo Ueno, Masahiro Nemoto, Wataru Uegami, Junya Fukuoka, Masafumi Misawa   +4 more
doaj   +1 more source

Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature

Thoracic Cancer, 2020
Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial.
Kazuaki Harada, Makoto Ogasawara, Akane Shido, Akimitsu Meno, Soichiro Oda, Shota Yoshida, Sonoe Yoshida, Ayumu Yoshikawa, Ko Ebata, Satoshi Abiko, Naoki Kawagishi, Itsuki Sano, Hisashi Oda, Takuto Miyagishima   +13 more
doaj   +1 more source

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival : an updated analysis of KEYNOTE-010 trial

, 2019
Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC).
Ahn, M-J, Baas, P, de Castro, G, Jr, Dubos Arvis, C, Emancipator, K, Felip, E, Fidler, MJ, Garon, EB, Garrido, M, Han, J-Y, Herbst, RS, Jensen, EH, Kim, D-W, Kim, J-H, Lubiniecki, GM, Majem, M, Molina, JR, Perez-Gracia, JL, Samkari, A, Shentu, Y, Surmont, Veerle   +20 more
core   +1 more source

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [PDF]

, 2018
The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 ...
Calleja Cervantes, M. E., Duruisseaux, M., Fernández Fernández, Agustín, Fernández Fraga, Mario, Martínez Cardús, A.   +4 more
core   +1 more source

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis

Thoracic Cancer, 2019
Recent clinical trials have demonstrated that anti‐PD‐1 blocking antibodies showed remarkable clinical efficacy in a subset of non‐small cell lung cancer (NSCLC) patients.
Akio Osa, Takeshi Uenami, Yujiro Naito, Haruhiko Hirata, Shohei Koyama, Takayuki Takimoto, Takayuki Shiroyama, Shinji Futami, Saeko Nakatsubo, Nobuhiko Sawa, Yukihiro Yano, Izumi Nagatomo, Yoshito Takeda, Masahide Mori, Hiroshi Kida, Atsushi Kumanogoh   +15 more
doaj   +1 more source

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Cancer Medicine, 2023
Background The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced ...
Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita   +15 more
doaj   +1 more source

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source